Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TARA Stock Summary
Top 10 Correlated ETFs
TARA
In the News

Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:30 am ET in New York.

Protara Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 11:20 am ET in New York, New York.

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More
The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Protara Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in fireside chats at two upcoming virtual conferences:

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022.

TARA Stock: Why The Price Increased This Past Week
The stock price of Protara Therapeutics Inc (NASDAQ: TARA) increased by over 5% during intraday trading. This is why it happened.

Biopharma Stock Skyrockets on FDA Approval
Biopharmaceutical stock Protara Therapeutics Inc (NASDAQ:TARA) is surging today, up 11.9% to trade at $7.55 at last check.
TARA Financial details
TARA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -9.93 | -2.52 | -4.63 | -4.2 | -5.76 | |
Operating cash flow per share | -9.07 | -2.68 | -3.24 | -3.07 | -2.35 | |
Free cash flow per share | -9.12 | -2.68 | -3.36 | -3.12 | -2.36 | |
Cash per share | 8.54 | 1.06 | 23.31 | 8.12 | 7.49 | |
Book value per share | 7.98 | 1.09 | 27.54 | 14.41 | 9.07 | |
Tangible book value per share | 7.98 | 1.09 | 23.46 | 11.79 | 9.07 | |
Share holders equity per share | 7.98 | 1.09 | 27.54 | 14.41 | 9.07 | |
Interest debt per share | 0 | 0 | 0.15 | 0.64 | 0.67 | |
Market cap | 232.49M | 95.84M | 175.13M | 75.82M | 30.18M | |
Enterprise value | 213.12M | 89.66M | 7.62M | 47.33M | 12.43M | |
P/E ratio | -9.14 | -6.51 | -5.23 | -1.61 | -0.47 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -10.01 | -6.13 | -7.48 | -2.2 | -1.14 | |
PFCF ratio | -9.96 | -6.12 | -7.21 | -2.16 | -1.14 | |
P/B Ratio | 11.37 | 14.99 | 0.88 | 0.47 | 0.3 | |
PTB ratio | 11.37 | 14.99 | 0.88 | 0.47 | 0.3 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -8.07 | -5.88 | -0.22 | -1 | -1.55 | |
EV to operating cash flow | -9.17 | -5.73 | -0.33 | -1.37 | -0.47 | |
EV to free cash flow | -9.13 | -5.72 | -0.31 | -1.35 | -0.47 | |
Earnings yield | -0.11 | -0.15 | -0.19 | -0.62 | -2.15 | |
Free cash flow yield | -0.1 | -0.16 | -0.14 | -0.46 | -0.88 | |
Debt to equity | 0 | 0 | 0.01 | 0.04 | 0.06 | |
Debt to assets | 0 | 0 | 0.01 | 0.04 | 0.06 | |
Net debt to EBITDA | 0.73 | 0.41 | 4.89 | 0.6 | 2.21 | |
Current ratio | 7.55 | 11.96 | 58.13 | 21.66 | 15.01 | |
Interest coverage | 0 | 0 | 0 | 0 | -58.98 | |
Income quality | 1.12 | 1.04 | 0.69 | 0.73 | 0.4 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0.15 | 0.17 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0.04 | 0.02 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.03 | -0.06 | -4.51 | -5.09 | -0.48 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 42.25 | 7.88 | 53.58 | 36.89 | 34.27 | |
ROIC | -1.54 | -2.34 | -0.17 | -0.27 | -0.57 | |
Return on tangible assets | -1.08 | -2.11 | -0.19 | -0.33 | -0.57 | |
Graham Net | 7.34 | 0.96 | 22.77 | 7.27 | 6.58 | |
Working capital | 20.16M | 6.39M | 166.52M | 88.81M | 80.41M | |
Tangible asset value | 20.44M | 6.39M | 169.73M | 132.4M | 102.08M | |
Net current asset value | 20.16M | 6.39M | 165.52M | 82.43M | 74.94M | |
Invested capital | 0 | 0 | 0.01 | 0.04 | 0.06 | |
Average receivables | 0 | 0 | 0 | 317K | 560K | |
Average payables | 366K | 352K | 588.5K | 934K | 1.27M | |
Average inventory | 0 | 0 | 0 | 607.5K | 1.19M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.24 | -2.3 | -0.17 | -0.29 | -0.63 | |
Capex per share | -0.05 | 0 | -0.12 | -0.05 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.73 | -0.66 | -3.45 | -0.74 | -1 | |
Operating cash flow per share | -0.46 | -0.47 | -0.45 | -1.14 | -0.83 | |
Free cash flow per share | -0.46 | -0.48 | -0.45 | -1.14 | -0.83 | |
Cash per share | 8.75 | 8.55 | 7.49 | 7.66 | 7.11 | |
Book value per share | 12.92 | 12.35 | 9.06 | 8.38 | 7.54 | |
Tangible book value per share | 10.3 | 9.73 | 9.06 | 8.38 | 7.54 | |
Share holders equity per share | 12.92 | 12.35 | 9.06 | 8.38 | 7.54 | |
Interest debt per share | 0.64 | 0.61 | 0.58 | 0.48 | 0.52 | |
Market cap | 32.98M | 33.35M | 30.2M | 35.38M | 27.03M | |
Enterprise value | 5.98M | -7.55M | 12.45M | 20.51M | -1.02M | |
P/E ratio | -1.01 | -1.13 | -0.19 | -1.06 | -0.6 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -6.44 | -6.24 | -6.01 | -2.75 | -2.87 | |
PFCF ratio | -6.41 | -6.14 | -6 | -2.74 | -2.87 | |
P/B Ratio | 0.23 | 0.24 | 0.3 | 0.37 | 0.32 | |
PTB ratio | 0.23 | 0.24 | 0.3 | 0.37 | 0.32 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -0.73 | 1.19 | 0.64 | -2.11 | 0.08 | |
EV to operating cash flow | -1.17 | 1.41 | -2.48 | -1.59 | 0.11 | |
EV to free cash flow | -1.16 | 1.39 | -2.47 | -1.59 | 0.11 | |
Earnings yield | -0.25 | -0.22 | -1.29 | -0.24 | -0.42 | |
Free cash flow yield | -0.16 | -0.16 | -0.17 | -0.36 | -0.35 | |
Debt to equity | 0.05 | 0.05 | 0.06 | 0.07 | 0.07 | |
Debt to assets | 0.04 | 0.04 | 0.06 | 0.06 | 0.06 | |
Net debt to EBITDA | 3.32 | 6.46 | -0.91 | 1.53 | 2.32 | |
Current ratio | 28.94 | 26.59 | 15.01 | 14.76 | 17.09 | |
Interest coverage | -25.16 | -29.1 | 191.35 | 14.17 | 0 | |
Income quality | 0.6 | 0.7 | 0.13 | 1.42 | 0.83 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.19 | 0.2 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.02 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.38 | -0.08 | 0.01 | -0.08 | -0.03 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 14.55 | 13.52 | 26.51 | 11.81 | 13.01 | |
ROIC | -0.05 | -0.05 | 0.18 | -0.08 | -0.12 | |
Return on tangible assets | -0.07 | -0.06 | -0.34 | -0.08 | -0.12 | |
Graham Net | 7.92 | 7.74 | 6.58 | 6.64 | 6.41 | |
Working capital | 97.6M | 94.96M | 80.41M | 88.21M | 79.33M | |
Tangible asset value | 115.94M | 109.66M | 102.08M | 94.77M | 85.23M | |
Net current asset value | 91.67M | 89.25M | 74.94M | 82.98M | 74.35M | |
Invested capital | 0.05 | 0.05 | 0.06 | 0.07 | 0.07 | |
Average receivables | 507.5K | 433.5K | 433K | 488.5K | 417.5K | |
Average payables | 466.5K | 424K | 1.02M | 2.83M | 2.97M | |
Average inventory | 1.04M | -243.5K | 581.5K | 336K | 1.53M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.06 | -0.05 | -0.38 | -0.09 | -0.13 | |
Capex per share | 0 | -0.01 | 0 | 0 | 0 |
TARA Frequently Asked Questions
What is Protara Therapeutics, Inc. stock symbol ?
Protara Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol TARA
What is Protara Therapeutics, Inc. stock quote today ?
Protara Therapeutics, Inc. stock price is $1.665 today.
Is Protara Therapeutics, Inc. stock public?
Yes, Protara Therapeutics, Inc. is a publicly traded company.